Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06725693 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 1 to 3v3
  2. Start date: Nov 1, 2024 to Feb 1, 2019v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the potential usefulness of 68Ga/18F-Exendin 4 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.
Trial Details
NCT Number NCT06725693
Lead Sponsor Tianjin Medical University
Collaborators: Tianjin Medical University General Hospital
Conditions
(from sponsor)		 GLP1-R-related Disease, Tumor, Insulinoma, Positron Emission Tomography
Related terms Insulinoma, Neoplasms
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov